Updates are available Correction dated 2021-01-28
Click to view Correction: https://doi.org/10.1038/s41388-021-01645-4
-
Authors
Han, Anna
Purwin, Timothy J. http://orcid.org/0000-0002-7053-8039
Bechtel, Nelisa
Liao, Connie
Chua, Vivian
Seifert, Erin
Sato, Takami
Schug, Zachary T. http://orcid.org/0000-0003-4197-8227
Speicher, David W.
Harbour, J. William
Aplin, Andrew E. http://orcid.org/0000-0002-2734-3244
-
Funding
Funding for this research was provided by:
American Association for Cancer Research
- License Information
-
More Information
Article History
Received: 3 July 2020
Revised: 22 October 2020
Accepted: 30 October 2020
First Online: 18 November 2020
Change Date: 14 January 2021
Change Type: Update
Change Details: The original published version was the given name from J. William Harbour incorrect tagged. It was given as J. (given name) William Harbour (family name) it was corrected to J. William (given name) Harbour (family name).
Change Date: 28 January 2021
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41388-021-01645-4
Compliance with ethical standards
:
: AEA reports receiving a commercial research grant from Pfizer Inc. (2013–2017) and has ownership interest in patent number 9880150. No potential conflicts of interest are disclosed by the other authors. JWH is the inventor of intellectual property related to prognostic testing for uveal melanoma. He is a paid consultant for Castle Biosciences, licensee of this intellectual property, and he receives royalties from its commercialization.
